What are the diagnostic criteria for Gitelman syndrome in a child, adolescent, or young adult presenting with hypokalemia, metabolic alkalosis, hypocalciuria, and possibly hypomagnesemia, with normal or low blood pressure and elevated renin/aldosterone after excluding diuretic use, vomiting, or diarrhea?

Diagnostic Criteria for Gitelman Syndrome

Gitelman syndrome is diagnosed by the characteristic biochemical tetrad of hypokalemia, metabolic alkalosis, hypomagnesemia, and hypocalciuria, after excluding diuretic use, vomiting, and diarrhea, with genetic confirmation via SLC12A3 mutation analysis when available.

Core Biochemical Criteria

The diagnosis rests on identifying the following laboratory abnormalities 1, 2:

• Hypokalemia (renal potassium wasting)
• Metabolic alkalosis
• Hypomagnesemia (often severe and persistent)
• Hypocalciuria (low urinary calcium excretion, distinguishing it from Bartter syndrome)

Additional supportive findings include:

• Normal or low blood pressure (hypotension common)
• Hyperreninemic hyperaldosteronism (secondary to salt wasting)
• Elevated fractional chloride excretion (>0.5%) 3

Critical Diagnostic Pitfalls

Normomagnesemia does not exclude Gitelman syndrome. Two important caveats emerge from the evidence:

1. Atypical presentations exist: Some genetically confirmed cases present with normomagnesemia 4, making hypomagnesemia a typical but not absolute requirement
2. Age of presentation varies: While classically diagnosed in adolescence or adulthood, early childhood presentations occur 2, 5, and diagnosis can be delayed into the sixth decade 6

Distinguishing from Bartter Syndrome

The key differentiating feature is urinary calcium excretion 3, 1:

• Gitelman syndrome: Hypocalciuria (low urinary calcium)
• Bartter syndrome: Normal to high urinary calcium excretion, often with nephrocalcinosis

Bartter syndrome typically presents earlier (prenatally or in infancy with polyhydramnios), while Gitelman syndrome rarely presents before age 6 years 1.

Genetic Confirmation

Molecular diagnosis via SLC12A3 gene sequencing is the gold standard 1, 7. Over 140 different mutations have been identified in the thiazide-sensitive NaCl cotransporter gene. However:

• A small minority have CLCNKB gene mutations (chloride channel ClC-Kb) 1
• Genetic heterogeneity exists: Some patients with classic biochemical features lack identifiable SLC12A3 mutations 6
• Clinical diagnosis remains valid when genetic testing is unavailable or negative with characteristic biochemical profile 5, 6

Functional Testing (Now Obsolete)

The 2021 European guidelines explicitly state that diuretic challenge tests are obsolete and not recommended 3. These tests (thiazide or furosemide administration) have been surpassed by genetic analysis and carry risk of severe volume depletion, particularly in children.

Practical Diagnostic Algorithm

1. Identify the biochemical pattern: Hypokalemia + metabolic alkalosis + hypomagnesemia + hypocalciuria
2. Exclude secondary causes: Rule out diuretic abuse, vomiting, diarrhea, laxative use
3. Assess urinary chloride: Fractional excretion >0.5% confirms renal salt wasting 3
4. Check blood pressure: Normal or low (excludes primary hyperaldosteronism)
5. Measure urinary calcium: Hypocalciuria distinguishes from Bartter syndrome
6. Pursue genetic testing: SLC12A3 sequencing (consider CLCNKB if negative)
7. Diagnose clinically if genetics unavailable: Characteristic biochemical profile suffices in resource-limited settings 5

Essential Exclusions Before Diagnosis

• Primary hyperaldosteronism
• Diuretic or laxative abuse (screen urine if suspected)
• Gastrointestinal losses (vomiting, diarrhea)
• Cystic fibrosis (pseudo-Bartter from salt loss in sweat) 3

The diagnosis can be made confidently on clinical and biochemical grounds alone when the classic tetrad is present and secondary causes are excluded, particularly in settings where genetic testing is unavailable 5, 6.